We are live on ! Find out more
NXTC icon

NextCure
NXTC

47 hedge funds and large institutions have $36M invested in NextCure in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

134% more capital invested

Capital invested by funds: $15.4M → $36M (+$20.6M)

9% more funds holding

Funds holding: 43 → 47 (+4)

0.81% more ownership

Funds ownership: 4.01% → 4.82% (+0.81%)

25% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 12

Holders
47
Holders Change
+4
Holders Change %
+9.3%
% of All Funds
0.68%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
9
Reduced
12
Closed
2
Calls
$23K
Puts
–
Net Calls
+$23K
Net Calls Change
+$23K

Top Buyers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
+$2.76M
2
AAA
Affinity Asset Advisors
New York
+$1.95M
3
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$613K
4
SSA
Schonfeld Strategic Advisors
New York
+$564K
5
CPA
Cardiff Park Advisors
California
+$376K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$2.25M
2
TCM
Tang Capital Management
California
-$464K
3
Citadel Advisors
Citadel Advisors
Florida
-$187K
4
BlackRock
BlackRock
New York
-$185K
5
AI
Acuitas Investments
Washington
-$73.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
26
Bridgeway Capital Management
Texas
$157K -$34.5K -2,000 -25%
Barclays
27
Barclays
United Kingdom
$151K – – –
MAM
28
Marquette Asset Management
Minnesota
$130K – – –
Two Sigma Advisers
29
Two Sigma Advisers
New York
$129K – – –
State Street
30
State Street
Massachusetts
$127K – – –
ACM
31
ADAR1 Capital Management
Texas
$95.9K -$25K -1,450 -29%
IC
32
IEQ Capital
California
$83.3K – – –
Northern Trust
33
Northern Trust
Illinois
$75.3K +$1.07K +62 +2%
LPL Financial
34
LPL Financial
California
$60.2K +$17.2K +997 +80%
XT
35
XTX Topco
Cayman Islands
$43.9K +$3.51K +204 +14%
HSBC Holdings
36
HSBC Holdings
United Kingdom
$38.7K – – –
UBS Group
37
UBS Group
Switzerland
$24.1K +$6.53K +379 +73%
HP
38
Harbourvest Partners
Massachusetts
$22.4K – – –
Charles Schwab
39
Charles Schwab
California
$22.3K – – –
Bank of America
40
Bank of America
North Carolina
$6.08K +$3.88K +225 +11,250%
TRCT
41
Tower Research Capital (TRC)
New York
$5.07K -$8.34K -484 -72%
Wells Fargo
42
Wells Fargo
California
$4.81K +$2.88K +167 +1,285%
JP Morgan Chase
43
JP Morgan Chase
New York
$1.79K -$999 -58 -46%
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$1.57K – – –
BNP Paribas Financial Markets
45
BNP Paribas Financial Markets
France
$859 – – –
Qube Research & Technologies (QRT)
46
Qube Research & Technologies (QRT)
United Kingdom
$107 – – –
VF
47
Virtu Financial
New York
– -$30K -2,213 Closed
Franklin Resources
48
Franklin Resources
California
– -$22.3K -1,632 Closed
Royal Bank of Canada
49
Royal Bank of Canada
Ontario, Canada
– -$362 -21 -95%
1
2

NXTC Hedge Fund Activity: Q1 2024 in Review

47 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in NextCure (NXTC) for Q1 2024, worth a combined $36M — up 134% from $15.4M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new NXTC positions and 2 closed out — a net gain of 4 holders — while 9 added to existing stakes and 12 trimmed.

The largest buyer was Logos Global Management, opening a new position worth an estimated $2.76M. The largest seller was OrbiMed, cutting an estimated $2.25M.

  • 47 institutional investors held NextCure (NXTC) as of Q1 2024, up from 43 in Q4 2023.
  • Funds reported $36M of NextCure stock for Q1 2024, up 134% quarter-over-quarter.
  • 6 funds opened new NextCure positions in Q1 2024 and 2 closed out, a net change of +4 holders.
  • The largest NextCure buyer in Q1 2024 was Logos Global Management, an estimated $2.76M added.
  • The largest NextCure seller in Q1 2024 was OrbiMed, an estimated $2.25M sold.

Based on aggregated 13F filings for Q1 2024.